Objective. Systemic lupus erythematosus (SLE) is characterized by B cell hyperactivity and autoantibody production. As spleen tyrosine kinase (Syk) is pivotal in B cell activation, these experiments aimed to examine the extent to which Syk was abnormally expressed in SLE B cells and the nature of the B cell subset that differently expressed Syk.Methods. B cells from healthy donors and SLE patients were analyzed by flow cytometry to assess basal expression of Syk and phosphorylated Syk. B cell subsets expressing higher levels of Syk were found, and their detailed phenotype, in vitro differentiation into plasmablasts/plasma cells, and Syk induction by cytokines were determined.
Conclusion. SLE patients exhibit an increased frequency of hitherto unknown CD27؊Syk؉؉ memorylike B cells, indicating that intracellular Syk density could distinguish CD27؊ memory B cells from truly naive B cell subsets. Furthermore, the CD27؊Syk؉؉ subset is a candidate for a source of increased plasma cells in SLE.B cell activation is a complex process involving different soluble and cellular components and, most importantly, if antigen-dependent, binding of the antigen to the B cell receptor (BCR). After BCR ligation, reorganization of autoregulatory BCR clusters with recruitment of intracellular kinases and subsequent internalization of the cognate antigen (1) initiate an intracellular signaling cascade by phosphorylation of the associated BCR molecules CD79␣ and CD79. In this process, other signaling molecules, such as Lyn, spleen tyrosine kinase (Syk), Bruton's tyrosine kinase (BTK), and phospholipase C␥2 (PLC␥2) are recruited and activated in an ordered manner to fine-tune BCR signaling. After BCR engagement, Syk becomes phosphorylated (tyrosine residues Y 348 and Y 352 ), induced by immunoreceptor tyrosine-based activation motifs (ITAMs) on the cytosolic tail of the BCRϪCD79 complex (2).Several studies have linked the development of murine lupus to abnormalities of BCR-associated signalSupported by the DFG (SFB650 project TP16, SFB633 A14, SPP ImmunoBone DFG Do491/8-2, and DFG project Do491/7-3).